Zhejiang Shengda Bio-Pharmaceutical Co., Ltd. releases its forecast for half-yearly earnings in 2024.

Sensex a shareJul 10 12:00 ET · Announcements

Zhejiang Shengda Bio-Pharm (603079.SH): Net profit in the first half of the year is expected to reach 180 million yuan to 220 million yuan.

On July 10th, Gelonhui announced that Zhejiang Shengda Bio-pharm (603079.SH) expects to achieve a net income of 18-22 million yuan owned by the parent company in the first half of 2024, compared to the same period last year (disclosed data), it will turn losses into profits. It is expected that the net income of deducting non-recurring gains and losses belonging to the parent company in the first half of 2024 will be from 4.6 million yuan to 5.8 million yuan. The company's product sales structure has been optimized compared to the same period last year.

Gelonghui FinanceJul 10 05:02 ET

Zhejiang Shengda Bio-pharm (603079.SH): Vitamin D3 is not the company's main product.

Shengda Bio-pharm (603079.SH) stated on the investor interaction platform that vitamin D3 is not our main product and does not meet disclosure requirements. The company's main vitamin products are biotin and folic acid. According to Boya Xunyu, in 2023, the company will be one of the top five suppliers of biotin and one of the top four suppliers of folic acid in China.

Gelonghui FinanceJul 3 03:40 ET

Zhejiang Shengda Bio-pharm (603079.SH) plans to distribute ¥0.6 per 10 shares in 2023. Ex-dividend date is June 12.

Zhejiang Shengda Bio-Pharm (603079.SH) announced that it plans to distribute a cash dividend of 0.60 yuan (including tax) per 10 shares to all shareholders in 2023. The ex-dividend date is June 12, 2024, and the shareholders' registration day is June 11, 2024.

Zhitong FinanceJun 3 07:24 ET

Shengda Biotech (603079.SH): The synthetic biology platform currently has a platform for strain construction, high-throughput screening, testing and fermentation

Gelonghui, May 7 | Shengda Biotech (603079.SH) said on the investor interactive platform that the company's synthetic biology platform currently has a platform for strain construction, high-throughput screening, testing and fermentation. The “Full Biosynthesis Technology and Green Manufacturing Demonstration for Major Vitamin Products” project jointly developed by the company and Zhejiang University aims to solve the problems of using toxic chemicals and high risk levels in traditional D-biotin production processes. At present, it has passed small test verification and fermentation process optimization, and has obtained 1 invention patent.

Gelonghui FinanceMay 7 05:42 ET

Synthetic organisms are now differentiated! Big bulls have advanced to the 5th straight board, and policy expectations haven't been met yet?

There will be major policies in the future

Gelonghui FinanceMay 7 01:29 ET